Mar 13, 2024 · Alirocumab is an injectable medicine that is given under your skin and may be used in adults with cardiovascular disease to reduce the risk of heart attack, stroke, and certain types of chest pain conditions (unstable angina); or to treat high blood chole

What is PRALUENT ® (alirocumab)? PRALUENT is an injectable prescription medicine used: in adults with cardiovascular disease to reduce the risk of heart attack, stroke, and certain types of chest pain conditions (unstable angina) requiring hospitalization.

Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors , and it was the first such agent ...

Alirocumab injection is used together with a proper diet and other medicines (eg, ezetimibe, statin medicine) to treat patients with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) or with homozygous familial hypercholesterolemia (HoFH), who need additional lowering of their bad cholesterol (LDL).

Aug 4, 2024 · Praluent (alirocumab) is commonly used for the following conditions. To lower the risk of heart attack, stroke, and chest pain requiring hospitalization in people with heart disease

Administer PRALUENT by subcutaneous injection into the thigh, abdomen, or upper arm using a single-dose pre-filled pen or single-dose pre-filled syringe. Rotate the injection site with each...

Alirocumab injection is in a class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor monoclonal antibodies. It works by blocking the production of LDL cholesterol in the body therefore decreasing the amount of cholesterol that may build up …

Medscape - Hypercholesterolemia dosing for Praluent (alirocumab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost...

Sep 3, 2024 · Alirocumab is a human monoclonal antibody (IgG1 isotype) that targets proprotein convertase subtilisin kexin type 9 (PCSK9). Alirocumab is a PCSK9 inhibitor produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.

Feb 19, 2018 · Alirocumab is a human monoclonal antibody to PCSK9 (proprotein convertase subtilisin/kexin type 9), a circulating protein that modulates the activity of the LDL cholesterol receptor in the liver. The monoclonal antibody lowers serum LDL cholesterol and is used to treat severe hypercholesterolemia.